编码SARS-CoV-2刺突蛋白的重组麻疹病毒经鼻内免疫在仓鼠中赋予针对COVID-19的保护性免疫
本研究将表达SARS-CoV-2刺突蛋白的重组麻疹病毒(rMeV-S)以5×10^5 PFU经肌内或鼻内途径接种叙利亚金黄仓鼠,随后以1×10^5 PFU SARS-CoV-2攻击,感染后4天安乐死。鼻内免疫rMeV-S可诱导保护性免疫反应,减轻体重下降和肺重量增加等病毒所致病理生理变化,并促进上呼吸道和肺内病毒清除。作者认为基于麻疹病毒平台的鼻内疫苗是有前景的策略。
要点
- 鼻内接种rMeV-S可诱导针对SARS-CoV-2的保护性免疫反应。
- 鼻内免疫减轻仓鼠体重下降和肺重量增加等病毒所致病理生理变化。
- 鼻内rMeV-S免疫促进肺和鼻洗液等样本中SARS-CoV-2清除。
核心结论
- 基于麻疹病毒平台的鼻内疫苗因契合病毒典型感染途径、接种便捷且可诱导强免疫反应,是有前景的策略。
研究设计与样本
- 制备表达SARS-CoV-2刺突蛋白的重组麻疹病毒rMeV-S,以5×10^5 PFU经肌内或鼻内途径接种叙利亚金黄仓鼠,随后以1×10^5 PFU SARS-CoV-2攻击,感染后4天安乐死。
主要发现
- 鼻内免疫rMeV-S可诱导保护性免疫反应,减轻仓鼠体重下降和肺重量增加等病毒所致病理生理变化。
- 肺免疫组化显示鼻内rMeV-S免疫诱导有效的SARS-CoV-2清除,与qRT-PCR测定的肺和鼻洗液样本病毒RNA含量、肺和鼻洗液及BALF样本SARS-CoV-2病毒滴度、血清RBD特异性IgG浓度及BALF中RBD特异性IgA浓度相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As the nasal mucosa is the initial site of infection for COVID-19, intranasal vaccines are more favorable than conventional vaccines. In recent clinical studies, intranasal immunization has been shown to generate higher neutralizing antibodies; however, there is a lack of evidence on sterilizing immunity in the upper airway. Previously, we developed a recombinant measles virus encoding the spike protein of SARS-CoV-2 (rMeV-S), eliciting humoral and cellular immune responses against SARS-CoV-2. OBJECTIVES: In this study, we aim to provide an experiment on nasal vaccines focusing on a measles virus platform as well as injection routes. STUDY DESIGN: Recombinant measles viruses expressing rMeV-S were prepared, and 5 × 105 PFUs of rMeV-S were administered to Syrian golden hamsters via intramuscular or intranasal injection. Subsequently, the hamsters were challenged with inoculations of 1 × 105 PFUs of SARS-CoV-2 and euthanized 4 days post-infection. Neutralizing antibodies and RBD-specific IgG in the serum and RBD-specific IgA in the bronchoalveolar lavage fluid (BALF) were measured, and SARS-CoV-2 clearance capacity was determined via quantitative reverse-transcription PCR (qRT-PCR) analysis and viral titer measurement in the upper respiratory tract and lungs. Immunohistochemistry and histopathological examinations of lung samples from experimental hamsters were conducted. RESULTS: The intranasal immunization of rMeV-S elicits protective immune responses and alleviates virus-induced pathophysiology, such as body weight reduction and lung weight increase in hamsters. Furthermore, lung immunohistochemistry demonstrated that intranasal rMeV-S immunization induces effective SARS-CoV-2 clearance that correlates with viral RNA content, as determined by qRT-PCR, in the lung and nasal wash samples, SARS-CoV-2 viral titers in lung, nasal wash, BALF samples, serum RBD-specific IgG concentration, and RBD-specific IgA concentration in the BALF. CONCLUSION: An intranasal vaccine based on the measles virus platform is a promising strategy owing to the typical route of infection of the virus, the ease of administration of the vaccine, and the strong immune response it elicits.
引用
- Park SI, Park S, Lee K, et al. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters. Vaccine. 2023. PMID: 38097457. doi:10.1016/j.vaccine.2023.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。